Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Reinhard Dummer, Helen Gogas(National and Kapodistrian University of Athens), Keith T. Flaherty(Massachusetts General Hospital), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(Ospedale Papa Giovanni XXIII), Gabriella Liszkay(National Institute of Oncology), Claus Garbe(University of Tübingen), Dirk Schadendorf(Deutschen Konsortium für Translationale Krebsforschung), Ivana Krajsová(Charles University), Ralf Gutzmer(Medizinische Hochschule Hannover), Jan Willem B. de Groot(Isala), Carmen Loquai(University Medical Center of the Johannes Gutenberg University Mainz), Ashwin Gollerkeri(Pfizer (United States)), Michael D. Pickard(Pfizer (United States)), Caroline Robert(Institut Gustave Roussy)
Cited by 175Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis